HilleVax’s norovirus vaccine failed a Phase 2b study in infants, but it’s not the end of the road for the biotech. A business deal this year brought HilleVax a Phase 1-ready norovirus vaccine candidate designed to offer even broader protection.
Summer weather is heating up but the market for IPOs remains cold. Bausch + Lomb’s successful return to the public markets in the second quarter proved to be an exception as the slowdown in IPO activity reached levels not seen in years.
Are you looking for a medical alert device that is elegant-looking and balances your independence and safety? Here are the best devices to choose from.
Takeda Pharmaceutical spinout HilleVax broke the biotech IPO drought with a $200 million stock market debut for clinical development of a norovirus vaccine. Two eye health companies marked the other IPO activity: Belite Bio went public while Bausch + Lomb set financial terms for what could become one of the biggest IPOs of the year.